STAT6 rs1059513: Allergic Rhinitis, Serum IgE, and Immunity
The single nucleotide polymorphism rs1059513 is a common genetic variant situated in the 3' untranslated region of the STAT6 gene on chromosome 12. STAT6 encodes a central transcription factor in the type 2 (Th2) immune signaling cascade that regulates immunoglobulin E production and allergic inflammation. Scientific studies have identified moderate associations between rs1059513 genotypes and variations in serum total IgE levels, allergic rhinitis risk, and related atopic manifestations.
What each genotype means
Increased allergic risk profile
The A allele of this variant has been identified in research as a risk factor associated with higher serum IgE levels, asthma, and atopic dermatitis. Individuals with this genotype may have a statistically higher predisposition to allergic conditions compared to those without the risk allele.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Intermediate allergic risk profile
Carrying one copy of the A allele is associated with an intermediate risk profile for elevated IgE levels and allergic conditions. Research suggests that the presence of the A allele influences STAT6 signaling, which plays a central role in the immune response to allergens.
This heterozygous genotype is frequently observed across diverse populations, reflecting the common nature of the A allele.
Baseline allergic risk profile
This genotype represents the absence of the A risk allele at this specific location. Individuals with this profile generally show lower statistical associations with the elevated IgE levels and allergic traits linked to the A allele in scientific literature.
This genotype is common, though its prevalence is highly dependent on the specific ancestral background of the population studied.
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs1059513 is situated on the long arm of human chromosome 12 at cytogenetic band 12q13.3, specifically located at position 57,095,926 on the GRCh38 assembly. Rather than changing an amino acid within the protein-coding sequence, rs1059513 is located in the 3' untranslated region (3' UTR) of the STAT6 gene. The variant represents a single base transition between thymine (T) and cytosine (C). Because it resides in an untranslated regulatory region, rs1059513 does not alter the primary peptide structure of the encoded protein; instead, non-coding variants in 3' untranslated regions are hypothesized to influence post-transcriptional mechanisms, such as mRNA stability, translation rate, or microRNA binding efficiency. In genetic epidemiology research, rs1059513 frequently serves as an informative tag single nucleotide polymorphism, capturing broader haplotype structures and regional linkage disequilibrium blocks across the STAT6 locus.
The Biological Function of STAT6 in Immune Pathways
The STAT6 gene encodes the Signal Transducer and Activator of Transcription 6 protein, a cytosolic transcription factor that acts as a vital conduit for type 2 immune responses. When upstream cytokines such as interleukin-4 (IL-4) or interleukin-13 (IL-13) bind to their respective cell surface receptor complexes, receptor-associated Janus kinases phosphorylate specific tyrosine residues on latent STAT6 monomers. Activated STAT6 proteins then homodimerize and translocate into the cell nucleus, where they bind responsive promoter elements to transcribe target genes. This pathway is essential for directing naive CD4+ helper T cells toward a Th2 lineage differentiation profile and directing B cells to execute class-switch recombination to immunoglobulin E (IgE). Because STAT6 orchestrates the body's allergic response mechanisms, regulatory genetic variation that modestly alters STAT6 transcript levels can ripple through the immune signaling network, modulating baseline immune sensitivity.
Research Associations with Serum IgE and Allergic Traits
Multiple genome-wide association studies and candidate gene cohort evaluations have identified rs1059513 as a notable marker for atopic traits. Genome-wide analyses, including investigations within the Framingham Heart Study, have repeatedly linked the locus containing rs1059513 to quantitative shifts in circulating total serum IgE concentrations. Additional studies have observed statistically significant associations between rs1059513 alleles and clinical allergic conditions such as allergic rhinitis, atopic eczema, and allergic asthma. Longitudinal cohorts, including the Isle of Wight birth study, have also evaluated epistatic effects, noting that combinations of risk genotypes across both IL13 (such as rs20541) and STAT6 (rs1059513) confer an interactive, compounding influence on eczema risk. Overall, scientific evidence supporting these associations is considered moderate; while statistical correlation is clear across large cohorts, individual effect sizes remain modest and can be mediated by environmental allergens.
Population Frequency and Demographic Patterns
The rs1059513 single nucleotide polymorphism occurs at varying frequencies across worldwide populations. In most global and continental reference datasets cataloged in dbSNP and the GWAS Catalog, the minor allele frequency typically spans between 0.25 and 0.35. However, regional ancestry cohorts present noticeable differences in distribution. In European-derived populations, such as cross-sectional groups studied in the United Kingdom and Iceland, the minor C allele frequency has been observed between approximately 0.10 and 0.18, with homozygous minor genotypes occurring in roughly 1% of sampled participants. In contrast, East Asian and several non-European ancestral cohorts exhibit higher minor allele frequencies, frequently exceeding 0.30. Because allele prevalence and linkage disequilibrium structures shift across ancestral groups, association effect sizes and disease odds ratios discovered in one population cannot always be generalized to individuals of different backgrounds.
Clinical Interpretation and Limitations
Genetic data regarding rs1059513 must be interpreted within the framework of complex, multifactorial inheritance. Carrying an allele statistically associated with higher baseline IgE or allergic sensitization does not mean a person will inevitably develop allergic rhinitis, asthma, or atopic dermatitis. Polygenic architectures mean that hundreds of small-effect variants across immune-regulatory genes collectively shape atopic predisposition, which is heavily modulated by environmental exposures like pollen, dust mites, microbial diversity, and diet. Consumers should understand that rs1059513 results are non-diagnostic and cannot confirm or rule out an allergic disease. While modern therapeutics like monoclonal antibodies directly target the IL-4/IL-13 and STAT6 signaling axis in severe type 2 inflammatory diseases, common single nucleotide polymorphisms like rs1059513 are not used to guide clinical medication regimens or drug dosing. Any treatment decisions should be directed by licensed healthcare providers.
How common is this variant?
The minor allele frequency for rs1059513 ranges from approximately 0.25 to 0.35 across diverse global cohorts, though it drops to roughly 0.10 to 0.18 in populations of European ancestry.
Frequently asked questions
Does having the rs1059513 risk allele mean I will develop severe allergies?
No. The rs1059513 variant confers only a modest statistical predisposition to higher IgE levels and allergic traits rather than causing allergic disease directly. Environmental allergens, lifestyle factors, and hundreds of other genes play a dominant role in determining whether clinical allergy symptoms actually appear.
Can an rs1059513 genetic test replace an allergy prick test or clinical blood test?
No, genetic testing for this single nucleotide polymorphism cannot replace clinical allergy evaluations. A medical allergy test measures specific allergen sensitization or immunoglobulin levels directly, whereas genotype testing merely reveals an inherited background tendency.
What is the biological connection between STAT6 and allergies?
STAT6 is a signaling protein that becomes activated when the immune system encounters cytokines like IL-4 and IL-13. Once activated, STAT6 switches on genes that tell immune cells to produce IgE antibodies and maintain Th2 inflammation, which are primary drivers of allergic symptoms.
Does this genetic variant affect how I should take allergy medications?
No, rs1059513 is not used in clinical practice to choose or adjust the dosage of allergy or asthma medications. You should always consult with your prescribing physician or a clinical pharmacist before starting, stopping, or altering any medication regimen.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1059513?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in STAT6
Intronic variant in STAT6 associated with elevated serum IgE levels and food allergy susceptibility.
An established intronic variant in STAT6 that enhances transcriptional activity and correlates with elevated serum total IgE levels and allergic rhinitis.
STAT6 intronic variant modulating IL-4/IL-13 signaling and associated with atopic dermatitis and asthma risk.
Intronic regulatory polymorphism in STAT6 associated with elevated serum IgE levels and mucosal allergic reactivity.
This variant is linked to the clinical phenotype of eosinophilic esophagitis, reflecting the role of immune regulation in the disease.